Concord Biotech Limited has announced the receipt of Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for its Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This approval is a significant milestone, strengthening the company’s market position in the U.S. and expanding its product portfolio in the critical immunosuppressant segment. The drug is vital for preventing organ rejection in transplant recipients.
USFDA Approval for Mycophenolate Mofetil
Concord Biotech Limited is pleased to report a significant development in its U.S. market expansion strategy. The company has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This approval marks a key achievement for Concord Biotech in the highly competitive pharmaceutical landscape.
Product Significance and Market Opportunity
Mycophenolate Mofetil is an essential antimetabolite immunosuppressant. It plays a crucial role in preventing organ rejection in adult and pediatric recipients, aged 3 months and older, who have undergone allogeneic kidney, heart, or liver transplants. The medication is typically administered in combination with other immunosuppressant therapies. This approval positions Concord Biotech to effectively capitalize on the estimated US$ 30 million U.S. market for Mycophenolate Mofetil. The company anticipates this will further enhance its product offerings and bolster its long-term growth trajectory in both U.S. and international markets.
Regulatory Compliance and Disclosure
This announcement is made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and related circulars. The company confirms that the approval received is in line with its strategic growth objectives and will reinforce its standing within the U.S. pharmaceutical sector. Further details pertaining to the approval, including its relevance and impact on the listed entity, are provided in the enclosed documents.
Company Leadership Endorsement
The approval signifies Concord Biotech’s commitment to innovation and its capability to meet stringent regulatory standards. The company looks forward to leveraging this achievement to strengthen its global presence and product pipeline.
Source: BSE
